These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20811370)

  • 41. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
    Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
    Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
    Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.
    Carpino PA; Goodwin B
    Expert Opin Ther Pat; 2010 Dec; 20(12):1627-51. PubMed ID: 21083519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
    Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
    Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deal watch: 'Big data' deal for diabetes clinical trial modelling.
    Harrison C
    Nat Rev Drug Discov; 2012 Nov; 11(11):822. PubMed ID: 23123931
    [No Abstract]   [Full Text] [Related]  

  • 50. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.
    Pfister M; Whaley JM; Zhang L; List JF
    Clin Pharmacol Ther; 2011 Apr; 89(4):621-5. PubMed ID: 21346749
    [No Abstract]   [Full Text] [Related]  

  • 51. Deal watch: Chiasma and Roche partner in oral peptide drug delivery.
    Harrison C
    Nat Rev Drug Discov; 2013 Apr; 12(4):255. PubMed ID: 23535927
    [No Abstract]   [Full Text] [Related]  

  • 52. Type 2 diabetes market.
    Gershell L
    Nat Rev Drug Discov; 2005 May; 4(5):367-8. PubMed ID: 15902771
    [No Abstract]   [Full Text] [Related]  

  • 53. Diabetes treatment.
    Bloomgarden ZT
    Diabetes Care; 2009 Mar; 32(3):e25-30. PubMed ID: 19246581
    [No Abstract]   [Full Text] [Related]  

  • 54. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
    Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An audience with...Marc Cluzel.
    Cluzel M
    Nat Rev Drug Discov; 2010 Jan; 9(1):14. PubMed ID: 20043024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
    Overton HA; Fyfe MC; Reynet C
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dapagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146
    [No Abstract]   [Full Text] [Related]  

  • 59. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
    Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
    Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel pharmacological approaches to the treatment of type 2 diabetes.
    Verspohl EJ
    Pharmacol Rev; 2012 Apr; 64(2):188-237. PubMed ID: 22407617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.